Literature DB >> 11930171

Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia.

Mikael Knutsson1, Lars Edvinsson.   

Abstract

The distribution of mRNA for pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 (PAC1) and vasoactive intestinal polypeptide (VIP) types 1 and 2 (VPAC1 and VPAC2, respectively) receptors was examined by reverse transcriptase polymerase chain reaction (RT-PCR) in human cerebral arteries and in trigeminal, otic, sphenopalatine and superior cervical ganglia. RT-PCR products of the expected sizes were detected in the arteries, in both the presence and absence of endothelium. In the majority (80%) of the trigeminal, otic and superior cervical ganglia, mRNA for all three receptors were found (n = 5). However, in the sphenopalatine ganglion neither VPAC2 nor PAC1 was detected (n = 2). This finding indicates the occurrence of both prejunctional (ganglia) and postjunctional (vessels) location of VIP and PACAP receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11930171     DOI: 10.1097/00001756-200203250-00030

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  25 in total

1.  PACAP receptor pharmacology and agonist bias: analysis in primary neurons and glia from the trigeminal ganglia and transfected cells.

Authors:  C S Walker; T Sundrum; D L Hay
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 2.  The PACAP receptor: a novel target for migraine treatment.

Authors:  Henrik W Schytz; Jes Olesen; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

3.  PACAP and its receptors in migraine pathophysiology: Commentary on Walker et al., Br J Pharmacol 171: 1521-1533.

Authors:  Lars Edvinsson
Journal:  Br J Pharmacol       Date:  2015-10       Impact factor: 8.739

Review 4.  Parasympathetic innervation of vertebrobasilar arteries: is this a potential clinical target?

Authors:  Eva V L Roloff; Ana M Tomiak-Baquero; Sergey Kasparov; Julian F R Paton
Journal:  J Physiol       Date:  2016-10-05       Impact factor: 5.182

Review 5.  Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.

Authors:  Tahlia Sundrum; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

Review 6.  Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine.

Authors:  Anne Luise Haulund Vollesen; Faisal Mohammad Amin; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

7.  Current understanding of trigeminal ganglion structure and function in headache.

Authors:  Karl Messlinger; Andrew F Russo
Journal:  Cephalalgia       Date:  2018-07-10       Impact factor: 6.292

Review 8.  Human models of migraine - short-term pain for long-term gain.

Authors:  Messoud Ashina; Jakob Møller Hansen; Bára Oladóttir Á Dunga; Jes Olesen
Journal:  Nat Rev Neurol       Date:  2017-10-06       Impact factor: 42.937

9.  Receptor activity modifying proteins (RAMPs) interact with the VPAC2 receptor and CRF1 receptors and modulate their function.

Authors:  D Wootten; H Lindmark; M Kadmiel; H Willcockson; K M Caron; J Barwell; T Drmota; D R Poyner
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

Review 10.  Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in central nervous system and inflammatory disorders.

Authors:  Terry W Moody; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-04-01       Impact factor: 3.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.